| Literature DB >> 28475811 |
Zhongbo Liu1, Tianzhen Han1, Shannon Fishman2, James Butler2, Tracy Zimmermann2, Frederic Tremblay2, Carole Harbison2, Nidhi Agrawal3, John J Kopchick4,5, Mitchell B Schaffler6, Shoshana Yakar1.
Abstract
Growth hormone (GH) and insulinlike growth factor 1 (IGF-1) are anabolic hormones that facilitate somatic and skeletal growth and regulate metabolism via endocrine and autocrine/paracrine mechanisms. We hypothesized that excess tissue production of GH would protect skeletal growth and integrity in states of reduction in serum IGF-1 levels. To test our hypothesis, we used bovine GH (bGH) transgenic mice as a model of GH hypersecretion and ablated the liver-derived acid-labile subunit, which stabilizes IGF-1 complexes with IGF-binding protein-3 and -5 in circulation. We used a genetic approach to create bGH/als gene knockout (ALSKO) mice and small interfering RNA (siRNA) gene-silencing approach to reduce als or igf-1 gene expression. We found that in both models, decreased IGF-1 levels in serum were associated with decreased body and skeletal size of the bGH mice. Excess GH produced more robust bones but compromised mechanical properties in male mice. Excess GH production in tissues did not protect from trabecular bone loss in response to reductions in serum IGF-1 (in bGH/ALSKO or bGH mice treated with siRNAs). Reduced serum IGF-1 levels in the bGH mice did not alleviate the hyperinsulinemia and did not resolve liver or kidney pathologies that resulted from GH hypersecretion. We concluded that reduced serum IGF-1 levels decrease somatic and skeletal growth even in states of excess GH.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28475811 PMCID: PMC5551555 DOI: 10.1210/en.2016-1952
Source DB: PubMed Journal: Endocrinology ISSN: 0013-7227 Impact factor: 4.736